Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 416

1.

Giants in Chest Medicine: Professor Emeritus Elizabeth F. Juniper, MCSP, MSc.

O'Byrne PM.

Chest. 2018 Apr;153(4):776-777. doi: 10.1016/j.chest.2018.01.017. No abstract available.

PMID:
29626968
2.

Interleukin-25 and eosinophils progenitor cell mobilization in allergic asthma.

Tang W, Smith SG, Du W, Gugilla A, Du J, Oliveria JP, Howie K, Salter BM, Gauvreau GM, O'Byrne PM, Sehmi R.

Clin Transl Allergy. 2018 Feb 13;8:5. doi: 10.1186/s13601-018-0190-2. eCollection 2018.

3.

Evolving Concepts in Asthma.

O'Byrne PM.

Semin Respir Crit Care Med. 2018 Feb;39(1):1-2. doi: 10.1055/s-0037-1620250. Epub 2018 Feb 10. No abstract available.

PMID:
29427979
4.

The effects of a CCR3 inhibitor, AXP1275, on allergen-induced airway responses in adults with mild-to-moderate atopic asthma.

Gauvreau GM, FitzGerald JM, Boulet LP, Watson RM, Hui L, Villineuve H, Scime TX, Schlatman AR, Obminski C, Kum J, Boehme S, Ly TW, Bacon KB, O'Byrne PM.

Clin Exp Allergy. 2018 Apr;48(4):445-451. doi: 10.1111/cea.13114. Epub 2018 Mar 13.

PMID:
29423947
5.

Sputum cytology during late-phase responses to inhalation challenge with different allergens.

Revez JA, Killian KJ, O'Byrne PM, Boulet LP, Upham JW, Gauvreau GM, Ferreira MAR.

Allergy. 2018 Jan 16. doi: 10.1111/all.13415. [Epub ahead of print]

PMID:
29337345
6.

Changes in regulatory B-cell levels in bone marrow, blood, and sputum of patients with asthma following inhaled allergen challenge.

Oliveria JP, El-Gammal AI, Yee M, Obminski CD, Scime TX, Watson RM, Howie K, O'Byrne PM, Sehmi R, Gauvreau GM.

J Allergy Clin Immunol. 2018 Apr;141(4):1495-1498.e9. doi: 10.1016/j.jaci.2017.11.013. Epub 2017 Dec 6. No abstract available.

7.

Novel Blood-based Transcriptional Biomarker Panels Predict the Late-Phase Asthmatic Response.

Singh A, Shannon CP, Kim YW, Yang CX, Balshaw R, Cohen Freue GV, Gauvreau GM, FitzGerald JM, Boulet LP, O'Byrne PM, Tebbutt SJ.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):450-462. doi: 10.1164/rccm.201701-0110OC.

PMID:
29087730
8.

The paradoxes of asthma management: time for a new approach?

O'Byrne PM, Jenkins C, Bateman ED.

Eur Respir J. 2017 Sep 9;50(3). pii: 1701103. doi: 10.1183/13993003.01103-2017. Print 2017 Sep. Review.

PMID:
28889114
9.

Methacholine Challenge: Comparison of Airway Responsiveness Produced by a Vibrating Mesh Nebulizer Versus a Jet Nebulizer.

Blais CM, Cockcroft DW, Veilleux J, Boulay MÈ, Boulet LP, Gauvreau GM, Scime TX, Watson RM, O'Byrne PM, Davis BE.

J Aerosol Med Pulm Drug Deliv. 2018 Apr;31(2):88-93. doi: 10.1089/jamp.2017.1392. Epub 2017 Aug 16.

PMID:
28813613
10.

Targeting Eosinophils in Eosinophilic Granulomatosis with Polyangiitis.

Djukanovic R, O'Byrne PM.

N Engl J Med. 2017 May 18;376(20):1985-1986. doi: 10.1056/NEJMe1704402. No abstract available.

PMID:
28514619
11.

Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment.

Jenkins CR, Eriksson G, Bateman ED, Reddel HK, Sears MR, Lindberg M, O'Byrne PM.

BMC Pulm Med. 2017 Apr 20;17(1):65. doi: 10.1186/s12890-017-0401-y.

12.

Allergen-induced Increases in Sputum Levels of Group 2 Innate Lymphoid Cells in Subjects with Asthma.

Chen R, Smith SG, Salter B, El-Gammal A, Oliveria JP, Obminski C, Watson R, O'Byrne PM, Gauvreau GM, Sehmi R.

Am J Respir Crit Care Med. 2017 Sep 15;196(6):700-712. doi: 10.1164/rccm.201612-2427OC.

PMID:
28422515
13.

The Potential Role of Aspiration in the Asthmatic Airway.

Hunt EB, Ward C, Power S, Sullivan A, Pearson JP, Lapthorne S, O'Byrne PM, Eustace J, Plant BJ, Maher MM, MacSharry J, Murphy DM.

Chest. 2017 Jun;151(6):1272-1278. doi: 10.1016/j.chest.2017.03.005. Epub 2017 Mar 11.

PMID:
28300572
14.

A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis.

Dasgupta A, Kjarsgaard M, Capaldi D, Radford K, Aleman F, Boylan C, Altman LC, Wight TN, Parraga G, O'Byrne PM, Nair P.

Eur Respir J. 2017 Mar 15;49(3). pii: 1602486. doi: 10.1183/13993003.02486-2016. Print 2017 Mar. No abstract available.

PMID:
28298405
15.

Toll-like receptor-induced expression of epithelial cytokine receptors on haemopoietic progenitors is altered in allergic asthma.

Tworek D, Heroux D, O'Byrne SN, Mitchell P, O'Byrne PM, Denburg JA.

Clin Exp Allergy. 2017 Jul;47(7):900-908. doi: 10.1111/cea.12913. Epub 2017 Mar 31.

PMID:
28252235
16.

The interaction between bronchoconstriction and cough in asthma.

Satia I, Badri H, Woodhead M, O'Byrne PM, Fowler SJ, Smith JA.

Thorax. 2017 Dec;72(12):1144-1146. doi: 10.1136/thoraxjnl-2016-209625. Epub 2017 Feb 24.

PMID:
28235887
17.

Methacholine challenge tests to demonstrate therapeutic equivalence of terbutaline sulfate via different Turbuhaler® devices in patients with mild to moderate asthma: Appraisal of a four-way crossover design.

Bjermer L, Gauvreau GM, Postma DS, O'Byrne PM, van den Berge M, Boulet LP, Beckman O, Persson T, Román J, Carlholm M, Schützer KM, Eckerwall G.

Pulm Pharmacol Ther. 2017 Jun;44:1-6. doi: 10.1016/j.pupt.2017.02.004. Epub 2017 Feb 20.

PMID:
28232118
18.

Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance.

Nair P, Martin JG, Cockcroft DC, Dolovich M, Lemiere C, Boulet LP, O'Byrne PM.

J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):649-659.e2. doi: 10.1016/j.jaip.2016.11.030. Epub 2017 Feb 2. Review.

PMID:
28163029
19.

The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials.

O'Byrne PM, FitzGerald JM, Zhong N, Bateman E, Barnes PJ, Keen C, Almqvist G, Pemberton K, Jorup C, Ivanov S, Reddel HK.

Trials. 2017 Jan 10;18(1):12. doi: 10.1186/s13063-016-1731-4.

20.

Therapeutic interventions in severe asthma.

Canonica GW, Senna G, Mitchell PD, O'Byrne PM, Passalacqua G, Varricchi G.

World Allergy Organ J. 2016 Nov 28;9(1):40. eCollection 2016. Review.

21.

Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation.

Mitchell PD, Salter BM, Oliveria JP, El-Gammal A, Tworek D, Smith SG, Sehmi R, Gauvreau GM, Butler M, O'Byrne PM.

Clin Exp Allergy. 2017 Mar;47(3):331-338. doi: 10.1111/cea.12860. Epub 2017 Jan 28.

PMID:
27928844
22.

Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study.

Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, Lythgoe D, O'Byrne PM.

Lancet. 2017 Jan 14;389(10065):157-166. doi: 10.1016/S0140-6736(16)31399-X. Epub 2016 Nov 30.

PMID:
27912982
23.

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma.

O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW.

Respir Res. 2016 Nov 24;17(1):157.

24.

Anti-IgE and Biologic Approaches for the Treatment of Asthma.

Mitchell PD, El-Gammal AI, O'Byrne PM.

Handb Exp Pharmacol. 2017;237:131-152. doi: 10.1007/164_2016_65. Review.

PMID:
27864676
25.

Epithelial-Derived Cytokines in Asthma.

Mitchell PD, O'Byrne PM.

Chest. 2017 Jun;151(6):1338-1344. doi: 10.1016/j.chest.2016.10.042. Epub 2016 Nov 3. Review.

PMID:
27818325
26.

Rebuttal From Dr O'Byrne.

O'Byrne PM.

Chest. 2017 Jan;151(1):20-21. doi: 10.1016/j.chest.2016.09.024. Epub 2016 Oct 13. No abstract available.

PMID:
27746206
27.

POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management? Yes.

O'Byrne PM.

Chest. 2017 Jan;151(1):14-17. doi: 10.1016/j.chest.2016.09.021. Epub 2016 Oct 13. No abstract available.

PMID:
27746203
28.

Revisiting early intervention in adult asthma.

Haahtela T, Selroos O, O'Byrne PM.

ERJ Open Res. 2015 Sep 14;1(1). pii: 00022-2015. eCollection 2015 May. Review.

29.

Allergen-Induced Increases in Interleukin-25 and Interleukin-25 Receptor Expression in Mature Eosinophils from Atopic Asthmatics.

Tang W, Smith SG, Salter B, Oliveria JP, Mitchell P, Nusca GM, Howie K, Gauvreau GM, O'Byrne PM, Sehmi R.

Int Arch Allergy Immunol. 2016;170(4):234-242. Epub 2016 Sep 30.

30.

The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.

Todd CM, Salter BM, Murphy DM, Watson RM, Howie KJ, Milot J, Sadeh J, Boulet LP, O'Byrne PM, Gauvreau GM.

Pulm Pharmacol Ther. 2016 Dec;41:34-39. doi: 10.1016/j.pupt.2016.09.005. Epub 2016 Sep 14.

PMID:
27640067
31.

Measuring Eosinophils to Make Treatment Decisions in Asthma.

Nair P, O'Byrne PM.

Chest. 2016 Sep;150(3):485-7. doi: 10.1016/j.chest.2016.07.009. No abstract available.

PMID:
27613975
32.

Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.

O'Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M, Larsson B, Cullberg M, Nair P.

Lancet Respir Med. 2016 Oct;4(10):797-806. doi: 10.1016/S2213-2600(16)30227-2. Epub 2016 Aug 27.

PMID:
27574788
33.

A dual CysLT1/2 antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma.

Gauvreau GM, Boulet LP, FitzGerald JM, Cockcroft DW, Davis BE, Leigh R, Tanaka M, Fourre JA, Tanaka M, Nabata T, O'Byrne PM.

Allergy. 2016 Dec;71(12):1721-1727. doi: 10.1111/all.12987. Epub 2016 Aug 9.

PMID:
27444660
34.

Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction.

Satia I, Tsamandouras N, Holt K, Badri H, Woodhead M, Ogungbenro K, Felton TW, O'Byrne PM, Fowler SJ, Smith JA.

J Allergy Clin Immunol. 2017 Mar;139(3):771-779.e10. doi: 10.1016/j.jaci.2016.04.045. Epub 2016 Jun 15.

35.

Biologics and the lung: TSLP and other epithelial cell-derived cytokines in asthma.

Mitchell PD, O'Byrne PM.

Pharmacol Ther. 2017 Jan;169:104-112. doi: 10.1016/j.pharmthera.2016.06.009. Epub 2016 Jun 27. Review.

PMID:
27365223
36.

Tiotropium for the treatment of asthma: a drug safety evaluation.

Kerstjens HA, O'Byrne PM.

Expert Opin Drug Saf. 2016 Aug;15(8):1115-24. doi: 10.1080/14740338.2016.1199682. Epub 2016 Jun 20. Review.

PMID:
27279414
37.

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.

Gauvreau GM, Arm JP, Boulet LP, Leigh R, Cockcroft DW, Davis BE, Mayers I, FitzGerald JM, Dahlen B, Killian KJ, Laviolette M, Carlsten C, Lazarinis N, Watson RM, Milot J, Swystun V, Bowen M, Hui L, Lantz AS, Meiser K, Maahs S, Lowe PJ, Skerjanec A, Drollmann A, O'Byrne PM.

J Allergy Clin Immunol. 2016 Oct;138(4):1051-1059. doi: 10.1016/j.jaci.2016.02.027. Epub 2016 Apr 7.

PMID:
27185571
38.

Surfactant Protein-D and Asthma.

Mitchell PD, O'Byrne PM.

Chest. 2016 May;149(5):1121-2. doi: 10.1016/j.chest.2015.12.038. No abstract available.

PMID:
27157209
39.

Identifying Molecular Mechanisms of the Late-Phase Asthmatic Response by Integrating Cellular, Gene, and Metabolite Levels in Blood.

Singh A, Shannon CP, Kim YW, DeMarco ML, Gauvreau GM, FitzGerald JM, Boulet LP, O'Byrne PM, Le Cao KA, Tebbutt SJ.

Ann Am Thorac Soc. 2016 Mar;13 Suppl 1:S98. doi: 10.1513/AnnalsATS.201510-694MG.

PMID:
27027968
40.

Allergen-induced Changes in Bone Marrow and Airway Dendritic Cells in Subjects with Asthma.

El-Gammal A, Oliveria JP, Howie K, Watson R, Mitchell P, Chen R, Baatjes A, Smith S, Al-Sajee D, Hawke TJ, Killian KJ, Gauvreau GM, O'Byrne PM.

Am J Respir Crit Care Med. 2016 Jul 15;194(2):169-77. doi: 10.1164/rccm.201508-1623OC.

PMID:
26844926
41.

Timing is everything: Targeting IgE to reduce asthma exacerbation risk.

O'Byrne PM, Tworek D.

J Allergy Clin Immunol. 2015 Dec;136(6):1486-1487. doi: 10.1016/j.jaci.2015.10.008. No abstract available.

PMID:
26654197
42.

IL-25 Receptor Expression on Airway Dendritic Cells after Allergen Challenge in Subjects with Asthma.

Tworek D, Smith SG, Salter BM, Baatjes AJ, Scime T, Watson R, Obminski C, Gauvreau GM, O'Byrne PM.

Am J Respir Crit Care Med. 2016 May 1;193(9):957-64. doi: 10.1164/rccm.201509-1751OC.

PMID:
26625138
43.

Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma.

Mitchell PD, El-Gammal AI, O'Byrne PM.

Clin Pharmacol Ther. 2016 Jan;99(1):38-48. doi: 10.1002/cpt.284. Epub 2015 Nov 18. Review.

PMID:
26502193
44.

Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies.

Bateman ED, Bousquet J, Aubier M, Bredenbröker D, O'Byrne PM.

Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S11-9. doi: 10.1016/j.pupt.2015.10.002. Epub 2015 Oct 8.

PMID:
26456372
45.

The Effects of Repeated Bronchoprovocation on FEV1 in Subjects with Asthma.

Janssen LJ, Gauvreau GM, Killian KJ, O'Byrne PM.

Ann Am Thorac Soc. 2015 Oct;12(10):1589-91. doi: 10.1513/AnnalsATS.201506-325LE. No abstract available.

PMID:
26448357
46.

Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma.

Bernstein DI, Bateman ED, Woodcock A, Toler WT, Forth R, Jacques L, Nunn C, O'Byrne PM.

J Asthma. 2015;52(10):1073-83. doi: 10.3109/02770903.2015.1056350. Epub 2015 Aug 18.

PMID:
26291137
47.

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.

O'Byrne PM, D'Urzo T, Beck E, Fležar M, Gahlemann M, Hart L, Blahova Z, Toorawa R, Beeh KM.

Respir Res. 2015 Aug 18;16:97. doi: 10.1186/s12931-015-0249-8.

48.

Roflumilast for asthma: Weighing the evidence.

Bateman ED, O'Byrne PM, Buhl R, Rabe KF.

Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S1-3. doi: 10.1016/j.pupt.2015.08.001. Epub 2015 Aug 13. No abstract available.

PMID:
26278190
49.

Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma.

Boulet LP, Gauvreau GM, Cockcroft DW, Davis B, Vachon L, Cormier Y, O'Byrne PM.

Can Respir J. 2015 Jul-Aug;22(4):230-4.

50.

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

Brightling CE, Chanez P, Leigh R, O'Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E.

Lancet Respir Med. 2015 Sep;3(9):692-701. doi: 10.1016/S2213-2600(15)00197-6. Epub 2015 Jul 28.

PMID:
26231288

Supplemental Content

Loading ...
Support Center